Crohn-betegség: vizsgálatok itt: Belgium

In Belgium 44 Also abroad 422

44 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 12.. Ask the study team whether a trial fits you.

3. fázisTaking people
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
Where
Gent, Leuven, Roeselare
Életkor
18 év and over
People
567 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to join2024-518296-56-00 · EU 2024-518296-56-00
3. fázisTaking people
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Where
Gent, Leuven, Roeselare
Életkor
16 év to 80 év
People
1200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00
3. fázisTaking people
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Where
Aalst, Brussels, Kortrijk, Leuven, Liège
Életkor
18 év to 70 év
People
290 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06937099 · EU 2024-520210-21-00
2. fázisTaking people
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
Where
Gent, Leuven, Roeselare
Életkor
18 év to 80 év
People
60 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07483073 · EU 2025-524112-11-00
2. fázisTaking people
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
Where
Ghent, Leuven, Roeselare
Életkor
18 év to 80 év
People
60 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07483099
3. fázisTaking people
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Gent, Jette, Leuven, Sint-Lambrechts-Woluwe
Életkor
2 év to 17 év
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05923073 · EU 2023-504735-41-00
3. fázisTaking people
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Where
Gent, Jette, Leuven
Életkor
3 év to 64 év
People
196 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00
2/3. fázisTaking people
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Where
Brussels, Gent, Leuven, Liège, Ostend, Sint-Lambrechts-Woluwe, Tournai
Életkor
18 év and over
People
1092 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07196722 · EU 2025-521382-27-00
No phaseTaking people
A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease
Where
Antwerp, Bonheiden, Brasschaat, Bruges, Brussels, Edegem, Ghent, Leuven, Liège, Ostend, Roeselare, Yvoir
Életkor
18 év and over
People
378 worldwide
Run by
Alimentiv Inc.
See details and how to joinNCT07363044
3. fázisTaking people
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Where
Brussels, Genk, Ghent, Leuven, Liège, Roeselare
Életkor
18 év and over
People
530 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07499232
3. fázisTaking people
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Where
Aalst, Edegem, Gent, Leuven, Roeselare, Sint-Lambrechts-Woluwe
Életkor
18 év and over
People
460 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07577843 · EU 2026-525922-39-00
2. fázisTaking people
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Where
Anderlecht, Brussels, Leuven, Liège
Életkor
18 év to 75 év
People
268 worldwide
Run by
Takeda
See details and how to joinNCT06233461 · EU 2023-506704-14-00
2. fázisTaking people
A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
Where
Leuven
Életkor
18 év to 75 év
People
99 worldwide
Run by
Sanofi
See details and how to joinNCT06958536 · EU 2024-517016-30-00
3. fázisTaking people
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Brussels, Edegem, Gent, Jette, Liège, Sint-Lambrechts-Woluwe
Életkor
16 év to 80 év
People
425 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819891 · EU 2024-513054-30-00
No phaseTaking people
Visceral Sensitivity in IBD (Irritable Bowel Disease) and IBS (Irritable Bowel Syndrome)
Where
Leuven
Életkor
18 év to 65 év
People
99 999 999
Run by
KU Leuven
See details and how to joinNCT02421705
3. fázisTaking people
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Genk, Liège, Sint-Niklaas, Yvoir
Életkor
16 év to 80 év
People
980 worldwide
Run by
Sanofi
See details and how to joinNCT07184931
3. fázisTaking people
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Yvoir
Életkor
16 év to 80 év
People
751 worldwide
Run by
Sanofi
See details and how to joinNCT07184944
3. fázisTaking people
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Brussels, Edegem, Jette, Leuven, Liège, Sint-Lambrechts-Woluwe
Életkor
2 év to 17 év
People
110 worldwide
Run by
AbbVie
See details and how to joinNCT05995353 · EU 2022-502050-14-00
3. fázisTaking people
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Aalst, Edegem, Gent, Liège, Mons, Sint-Niklaas
Életkor
16 év to 80 év
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00
2. fázisTaking people
A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease
Where
Bonheiden, Gent, Leuven, Liège, Roeselare, Sint-Lambrechts-Woluwe, Yvoir
Életkor
18 év and over
People
160 worldwide
Run by
Agomab Spain S.L.U.
See details and how to join2026-525197-19-00 · EU 2026-525197-19-00
3. fázisTaking people
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Where
Liège, Sint-Lambrechts-Woluwe
Életkor
2 év to 17 év
People
70 worldwide
Run by
Takeda
See details and how to joinNCT06405087 · EU 2023-508804-39-00
3. fázisTaking people
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Where
Brussels, Edegem, Ghent, Leuven
Életkor
2 év to 19 év
People
150 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT04844606
3. fázisTaking people
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Where
Gent, Jette, Leuven, Sint-Lambrechts-Woluwe
Életkor
2 év to 17 év
People
90 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05509777 · EU 2024-511472-32-00
2. fázisTaking people
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Where
Anderlecht, Bonheiden, Brussels, Kortrijk, Leuven, Liège, Ostend, Sint-Lambrechts-Woluwe, Yvoir
Életkor
18 év to 75 év
People
590 worldwide
Run by
AbbVie
See details and how to joinNCT06548542 · EU 2024-513009-30-00
No phaseTaking people
Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in Belgium
Where
Anderlecht, Bonheiden, Genk, Ghent, Kortrijk, Liège, Lodelinsart, Roeselare, Sint-Niklaas, Tournai
Életkor
18 év and over
People
280
Run by
AbbVie
See details and how to joinNCT06581042